Samsung Biologics207940
Samsung Biologics (207940) Amended Rights Offering, Nov 5, 2026
Filing date ·
Samsung Biologics filed a correction to its November 5, 2026 rights offering, setting the final issue price at KRW 1.174 million per common share.
Sign in to read this filing in detail
Continue to the filing details and any available analysis after signing in.
Filing lists and official source links are available without signing in.